Finding novel pathways such as the mortalin-HSP60 axis and its regulatory elements can be a new platform for a therapeutic approach that not only effectively represses primary tumor progression but also suppresses the development of metastatic characteristics interfering with overactive mitochondria. This evidence concerns the gene HSPA9 and neoplasm.